Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor

Despite advances in HIV‐1 management with antiretroviral therapy, drug resistance and toxicities with multidrug regimens can result in treatment failure. Hence, there is a continuing demand for antiretroviral agents (ARVs) with novel mechanisms of action. Maturation inhibitors inhibit HIV‐1 replicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Joshi, Samit R., Fernando, Disala, Igwe, Stephanie, McKenzie, Litza, Krishnatry, Anu S., Halliday, Fiona, Zhan, Joyce, Greene, Thomas J., Xu, Jianfeng, Ferron‐Brady, Geraldine, Lataillade, Max, Min, Sherene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670640/
https://www.ncbi.nlm.nih.gov/pubmed/33200887
http://dx.doi.org/10.1002/prp2.671

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7670640/
https://www.ncbi.nlm.nih.gov/pubmed/33200887
http://dx.doi.org/10.1002/prp2.671

Ejemplares similares